Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kevin C Lindquist"'
Autor:
Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff53
Autor:
Christine Bee, Yasmina N Abdiche, Donna M Stone, Sierra Collier, Kevin C Lindquist, Alanna C Pinkerton, Jaume Pons, Arvind Rajpal
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e36261 (2012)
Therapeutic antibodies are often engineered or selected to have high on-target binding affinities that can be challenging to determine precisely by most biophysical methods. Here, we explore the dynamic range of the kinetic exclusion assay (KinExA) b
Externí odkaz:
https://doaj.org/article/bfa742b2de654aae86a03ebbcd9b137a
Autor:
Wei Chen, Fan Yang, Carole Wang, Jatin Narula, Edward Pascua, Irene Ni, Sheng Ding, Xiaodi Deng, Matthew Ling-Hon Chu, Amber Pham, Xiaoyue Jiang, Kevin C. Lindquist, Patrick J. Doonan, Tom Van Blarcom, Yik Andy Yeung, Javier Chaparro-Riggers
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-bind
Externí odkaz:
https://doaj.org/article/689b1a83bc0d495ead97d93c01362efb
Autor:
Barbra J. Sasu, Javier Chaparro-Riggers, Pavel Strop, Arvind Rajpal, David Shelton, Jeffrey L. Wolf, Thomas G. Martin, Bernard Buetow, Ingrid Pardo, Michael Mirsky, Bora Han, Bing Kuang, Allison G. Chunyk, Kevin C. Lindquist, Yik Andy Yeung, Thomas J. Van Blarcom, Sherman M. Chin, Russell G. Dushin, Marjorie Bateman, Santiago Farias, Kathy Delaria, Wei Chen, Edward Pascua, Cris Kamperschroer, Laura Aschenbrenner, Tao Geng, Amy Chen, Yi Zhang, Tracy C. Kuo, Siler H. Panowski
BCMA bispecific is highly active in vivo.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::748b3e6c190c08ac317b01e7ce3f2069
https://doi.org/10.1158/1535-7163.22510278
https://doi.org/10.1158/1535-7163.22510278
Autor:
Barbra J. Sasu, Javier Chaparro-Riggers, Pavel Strop, Arvind Rajpal, David Shelton, Jeffrey L. Wolf, Thomas G. Martin, Bernard Buetow, Ingrid Pardo, Michael Mirsky, Bora Han, Bing Kuang, Allison G. Chunyk, Kevin C. Lindquist, Yik Andy Yeung, Thomas J. Van Blarcom, Sherman M. Chin, Russell G. Dushin, Marjorie Bateman, Santiago Farias, Kathy Delaria, Wei Chen, Edward Pascua, Cris Kamperschroer, Laura Aschenbrenner, Tao Geng, Amy Chen, Yi Zhang, Tracy C. Kuo, Siler H. Panowski
Tables show PK kinetics, plasma cell numbers, and patient data. Methods include all supplemental methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f21b0175c33170d2642c58ea1c4072b
https://doi.org/10.1158/1535-7163.22510263
https://doi.org/10.1158/1535-7163.22510263
Autor:
Barbra J. Sasu, Javier Chaparro-Riggers, Pavel Strop, Arvind Rajpal, David Shelton, Jeffrey L. Wolf, Thomas G. Martin, Bernard Buetow, Ingrid Pardo, Michael Mirsky, Bora Han, Bing Kuang, Allison G. Chunyk, Kevin C. Lindquist, Yik Andy Yeung, Thomas J. Van Blarcom, Sherman M. Chin, Russell G. Dushin, Marjorie Bateman, Santiago Farias, Kathy Delaria, Wei Chen, Edward Pascua, Cris Kamperschroer, Laura Aschenbrenner, Tao Geng, Amy Chen, Yi Zhang, Tracy C. Kuo, Siler H. Panowski
The restricted expression pattern of B-cell maturation antigen (BCMA) makes it an ideal tumor-associated antigen (TAA) for the treatment of myeloma. BCMA has been targeted by both CD3 bispecific antibody and antibody–drug conjugate (ADC) modalities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e53d5a22469996870b78467034a668
https://doi.org/10.1158/1535-7163.c.6539562.v1
https://doi.org/10.1158/1535-7163.c.6539562.v1
Autor:
Spencer Park, Edward Pascua, Kevin C. Lindquist, Christopher Kimberlin, Xiaodi Deng, Yvonne S. L. Mak, Zea Melton, Theodore O. Johnson, Regina Lin, Bijan Boldajipour, Robert T. Abraham, Jaume Pons, Barbra Johnson Sasu, Thomas J. Van Blarcom, Javier Chaparro-Riggers
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Many next-generation antibody therapeutics have enhanced potency but the risk of adverse events. Here the authors develop a conditionally activated, single-module CAR.
Externí odkaz:
https://doaj.org/article/a6c74f8c5d424b06a2dbc5aa3382a4ec